prohibitin-targeting peptide 1 A chimeric, 25-mer peptide that targets prohibitin - AdipotidepeptideDosage Chart CKGGRAKDC (SEQ ID NO: 1) targeting peptide associates with prohibitin Prohibitin-Targeting Peptide 1: A Novel Approach to Obesity and Cancer Treatment

Adipotidepeptideresults Prohibitin-targeting peptide 1 (Prohibitin-TP01), also known as adipotide, represents a significant advancement in therapeutic strategies, particularly for conditions like obesity and certain cancers. This chimeric, 25-mer peptide is engineered to precisely target prohibitin, a protein found to be crucial in various cellular functions, including adipocyte biology and cancer cell proliferation. Its innovative mechanism of action focuses on disrupting the function of specific tissues, offering a more localized and potentially less toxic therapeutic approachA first-in-man, Phase I evaluation of a single cycle ofprohibitin targeting peptide 1in patients with metastatic prostate cancer and obesity..

At its core, Prohibitin-TP01 operates by selectively binding to prohibitin. This protein is notably expressed on the surface of adipose cells, making it a prime target for weight loss interventions. By targeting specific blood vessels supplying adipose tissue with blood, adipotide causes these vessels to shrink, thereby reducing the blood supply to fat cells. This mechanism effectively leads to the destruction of white fat, the type of fat commonly associated with metabolic issues and obesity, particularly in men. Research has demonstrated that peptides like Prohibitin-TP01 can induce apoptosis in adipocytes, leading to significant reduction of body weight in preclinical models, such as the high-fat diet-induced obesity mouse model.

Beyond its anti-obesity applications, the targeting capabilities of Prohibitin-TP01 have also been explored in oncologyUS20130237476A1 - Adipose tissue targeted peptides. Prohibitin is implicated in the proliferation of certain cancer cells, and by targeting prohibitin, Adipotide has shown potential as an antineoplastic agent2026年1月3日—Thesepeptidesdemonstrate significant reduction of body weight in a high-fat diet-induced obesity mouse model and represent a paradigm shift in .... Studies have investigated its use in conjunction with chemotherapy or as a standalone treatment, aiming to induce prohibitin-TP01 mediated tumor cell death.Prohibitin Inactivation in Adipocytes Results in Reduced ... For instance, the CKGGRAKDC peptide, known to associate with prohibitin, has been identified as a key component in such therapeutic strategies. This CKGGRAKDC (SEQ ID NO: 1) targeting peptide associates with prohibitin due to prohibitin's role as a multifunctional membrane-associated protein.

The development of Prohibitin-targeting peptide 1 has involved extensive research and clinical trials. A first-in-man, Phase I evaluation of Prohibitin-TP01 investigated its tolerability and safety profile in patients with advanced conditions, including metastatic prostate cancer and obesity. The primary goal of such trials is to determine the highest tolerable dose of PROHIBITIN-TP01 that can be safely administered.prohibitin-TP01 While the precise Adipotide peptide dosage can vary depending on the study and patient population, the focus remains on optimizing efficacy while minimizing adverse effects.

Various iterations and related compounds have emerged from this research. HKPao (Hunter-killer peptide ao) is another biologically active peptide that shares similar anti-obesity and anti-tumor apoptotic activities. Furthermore, the concept of vascular-targeted nanotherapy for obesity has utilized prohibitin-targeted nanoparticles (PTNP), where a peptide ligand is conjugated to deliver therapeutic agents directly to adipose tissue.Prohibitin-targeting peptide 1 These nanoparticles, modified with a prohibitin-homing peptide like KGGRAKDC, function as a targeting motif.

The scientific community continues to explore the full potential of these targeting prohibitin peptides. Research efforts are focused on refining the delivery mechanisms, understanding the Adipotide peptide benefits, and characterizing potential Adipotide peptide side effects. Studies involving mixed-chirality prohibitin peptides and fatty liver/adipose tissue dual-targeting nanoparticles further illustrate the ongoing innovation in this field. The ability of Adipotide to selectively destroy white fat and its potential anti-cancer properties underscore its significance as a promising therapeutic candidateA first-in-man, Phase I evaluation of a single cycle ofprohibitin targeting peptide 1in patients with metastatic prostate cancer and obesity.. As research progresses, the precise Adipotide peptide how to use and optimal Adipotide peptide results will become clearer, paving the way for its broader clinical application.